 | • レポートコード：MRC2302E0114 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、233ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に1,199.03百万ドルであった世界のC反応性タンパク質検査市場規模が、2022年に1,344.57百万ドルになり、2027年まで年平均12.31%で成長して2,406.93百万ドルに達すると予測しています。本レポートでは、C反応性タンパク質検査の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、疾患別（癌、循環器疾患、子宮内膜症、炎症性腸疾患、ループス）分析、エンドユーザー別（生活支援型医療施設、診療所、家庭、病院、ラボ）分析、アッセイ種類別（ケミルミネッセンスイムノアッセイ、ELISA、免疫比濁法、ラジオイムノアッセイ）分析、検出範囲別（cCRP、従来型CRP、hs-CRP）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。また、本書には、Abaxis, Inc.、Abbott Laboratories、Abcam plc、Aidian、Alere Inc.、Beckman Coulter, Inc.、Bio-Techne、BODITECH MED, INC、Danaher、EKF Diagnostics、Eurolyser Diagnostica GmbH、F. Hoffmann-La Roche Ltd.、Getein Biotech, Inc.、HORIBA, Ltd.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のC反応性タンパク質検査市場規模：疾患別 - 癌検査における市場規模 - 循環器疾患検査における市場規模 - 子宮内膜症検査における市場規模 - 炎症性腸疾患検査における市場規模 - ループス検査における市場規模 ・世界のC反応性タンパク質検査市場規模：エンドユーザー別 - 生活支援型医療施設における市場規模 - 診療所における市場規模 - 家庭における市場規模 - 病院における市場規模 - ラボにおける市場規模 ・世界のC反応性タンパク質検査市場規模：アッセイ種類別 - ケミルミネッセンスイムノアッセイの市場規模 - ELISAの市場規模 - 免疫比濁法の市場規模 - ラジオイムノアッセイの市場規模 ・世界のC反応性タンパク質検査市場規模：検出範囲別 - cCRPの市場規模 - 従来型CRPの市場規模 - hs-CRPの市場規模 ・世界のC反応性タンパク質検査市場規模：地域別 - 南北アメリカのC反応性タンパク質検査市場規模 アメリカのC反応性タンパク質検査市場規模 カナダのC反応性タンパク質検査市場規模 ブラジルのC反応性タンパク質検査市場規模 ... - アジア太平洋のC反応性タンパク質検査市場規模 日本のC反応性タンパク質検査市場規模 中国のC反応性タンパク質検査市場規模 インドのC反応性タンパク質検査市場規模 韓国のC反応性タンパク質検査市場規模 台湾のC反応性タンパク質検査市場規模 ... -ヨーロッパ/中東/アフリカのC反応性タンパク質検査市場規模 イギリスのC反応性タンパク質検査市場規模 ドイツのC反応性タンパク質検査市場規模 フランスのC反応性タンパク質検査市場規模 ロシアのC反応性タンパク質検査市場規模 ... -その他地域のC反応性タンパク質検査市場規模 ・競争状況 ・企業情報 |
The Global C-Reactive Protein Testing Market size was estimated at USD 1,199.03 million in 2021 and expected to reach USD 1,344.57 million in 2022, and is projected to grow at a CAGR 12.31% to reach USD 2,406.93 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the C-Reactive Protein Testing to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Disease Area, the market was studied across Cancer, Cardiovascular Diseases, Endometriosis, Inflammatory Bowel Disease, Lupus, and Rheumatoid Arthritis.
Based on End-user, the market was studied across Assisted Living Healthcare Facilities, Clinics, Home, Hospitals, and Laboratories. The Clinics is further studied across Entity. The Entity is further studied across Physician Offices and Small Clinics.
Based on Assay Type, the market was studied across Chemiluminescence Immunoassay, ELISA, Immunoturbidimetric Assay, and Radioimmunoassay. The Chemiluminescence Immunoassay is further studied across Free T3, Free T4, and Thyrotropin (TSH) levels. The ELISA is further studied across Clinical and Nonclinical. The Radioimmunoassay is further studied across Autoantibodies Against Thyrotropin Receptor, Human Serum Thyroglobulin Autoantibodies, and Thyroperoxidase Autoantibodies.
Based on Detection Range, the market was studied across cCRP, Conventional CRP, and hs-CRP.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for C-Reactive Protein Testing market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the C-Reactive Protein Testing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global C-Reactive Protein Testing Market, including Abaxis, Inc., Abbott Laboratories, Abcam plc, Aidian, Alere Inc., Beckman Coulter, Inc., Bio-Techne, BODITECH MED, INC, Danaher, EKF Diagnostics, Eurolyser Diagnostica GmbH, F. Hoffmann-La Roche Ltd., Getein Biotech, Inc., HORIBA, Ltd., Laboratory Corporation of America Holdings (LabCorp), Merck KGaA, Merck Millipore, Ortho Clinical Diagnostics, Quest Diagnostics Incorporated, Randox Laboratories Ltd., SD Biosensor, INC., Siemens, Sigma-Aldrich Co. LLC, and Thermo Fisher Scientific, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global C-Reactive Protein Testing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global C-Reactive Protein Testing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global C-Reactive Protein Testing Market?
4. What is the competitive strategic window for opportunities in the Global C-Reactive Protein Testing Market?
5. What are the technology trends and regulatory frameworks in the Global C-Reactive Protein Testing Market?
6. What is the market share of the leading vendors in the Global C-Reactive Protein Testing Market?
7. What modes and strategic moves are considered suitable for entering the Global C-Reactive Protein Testing Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing R&D for C-reactive protein testing
5.1.1.2. Need to measure inflammation caused by a wide variety of conditions, from infection to cancer
5.1.1.3. Rising incidence of chronic disorders
5.1.2. Restraints
5.1.2.1. Availability of more commercialised alternative disease testing methods
5.1.3. Opportunities
5.1.3.1. Technological advancements pertaining to conventional CRP tests
5.1.3.2. Growing attrctiveness of point-of-care tests
5.1.4. Challenges
5.1.4.1. Careful administration and handling requirements
5.2. Cumulative Impact of COVID-19
6. C-Reactive Protein Testing Market, by Disease Area
6.1. Introduction
6.2. Cancer
6.3. Cardiovascular Diseases
6.4. Endometriosis
6.5. Inflammatory Bowel Disease
6.6. Lupus
6.7. Rheumatoid Arthritis
7. C-Reactive Protein Testing Market, by End-user
7.1. Introduction
7.2. Assisted Living Healthcare Facilities
7.3. Clinics
7.4.1. Entity
7.4.2.1. Physician Offices
7.4.2.2. Small Clinics
7.4. Home
7.5. Hospitals
7.6. Laboratories
8. C-Reactive Protein Testing Market, by Assay Type
8.1. Introduction
8.2. Chemiluminescence Immunoassay
8.3.1. Free T3
8.3.2. Free T4
8.3.3. Thyrotropin (TSH) levels
8.3. ELISA
8.4.1. Clinical
8.4.2. Nonclinical
8.4. Immunoturbidimetric Assay
8.5. Radioimmunoassay
8.6.1. Autoantibodies Against Thyrotropin Receptor
8.6.2. Human Serum Thyroglobulin Autoantibodies
8.6.3. Thyroperoxidase Autoantibodies
9. C-Reactive Protein Testing Market, by Detection Range
9.1. Introduction
9.2. cCRP
9.3. Conventional CRP
9.4. hs-CRP
10. Americas C-Reactive Protein Testing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific C-Reactive Protein Testing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa C-Reactive Protein Testing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abaxis, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Abbott Laboratories
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Abcam plc
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Aidian
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Alere Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Beckman Coulter, Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Bio-Techne
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. BODITECH MED, INC
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Danaher
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. EKF Diagnostics
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Eurolyser Diagnostica GmbH
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. F. Hoffmann-La Roche Ltd.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Getein Biotech, Inc.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. HORIBA, Ltd.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Laboratory Corporation of America Holdings (LabCorp)
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Merck KGaA
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Merck Millipore
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Ortho Clinical Diagnostics
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Quest Diagnostics Incorporated
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Randox Laboratories Ltd.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. SD Biosensor, INC.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Siemens
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Sigma-Aldrich Co. LLC
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Thermo Fisher Scientific, Inc.
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing